PXG-CycK / Proxygen - LARVOL DELTA

PXG-CycK, a highly selective molecular glue degrader of Cyclin K with potent anti-tumor activity in HER2-amplified cancers (AACR-NCI-EORTC 2025) - "PXG-CycK represents a Cyclin K degrader with best-in-class profile with a novel mechanism of action, exceptional CDK selectivity, and a compelling preclinical safety profile. Its robust activity in HER2-driven models positions it as a promising candidate for clinical development in breast and other solid tumors. These attributes position PXG-CycK as a promising therapeutic candidate, now advancing into clinical development, and offer a compelling new class of drugs in HER2-positive cancers, other CDK12/Cyclin K-dependent malignancies and Homologous Repair-deficient tumors, such as TNBC and ovarian cancer."

Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • CDK12 • CDK13 • CDK7 • CDK9 • HER-2

PXG-CycK, a highly selective molecular glue degrader of Cyclin K with potent anti-tumor activity in HER2-amplified cancers* (AACR-NCI-EORTC 2025) - "PXG-CycK represents a Cyclin K degrader with best-in-class profile with a novel mechanism of action, exceptional CDK selectivity, and a compelling preclinical safety profile. Its robust activity in HER2-driven models positions it as a promising candidate for clinical development in breast and other solid tumors. These attributes position PXG-CycK as a promising therapeutic candidate, now advancing into clinical development, and offer a compelling new class of drugs in HER2-positive cancers, other CDK12/Cyclin K-dependent malignancies and Homologous Repair-deficient tumors, such as TNBC and ovarian cancer."

Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • CDK12 • CDK13 • CDK7 • CDK9 • HER-2